The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

Leukemia

Volumn 25, Issue 4, 2011, Pages 638-647

  Durig J ^a   Duhrsen U ^a   Klein Hitpass, L ^a   Worm, J ^b   Hansen, J B R ^b   Orum, H ^b   Wissenbach, M ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Santaris Pharma AS   (Denmark)

Author keywords

Bcl 2 antisense; CLL; gene expression profiling

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN M; LOCKED NUCLEIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2; SPC 2996; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; MALE; MICROARRAY ANALYSIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 79954438975     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.322     Document Type: Article

References (33)

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer InstituteFWorking Group 1996 guidelines. Blood 2008; 111: 5446-5456.
2. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Opt Oncol 2003; 4: 211-218.
3. Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005; 19: 213-221. (Pubitemid 40387412)
4. Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007; 3: 855-870. (Pubitemid 350162084)
5. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120. (Pubitemid 46596764)
6. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27: 5208-5212.
7. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 7697-7702. (Pubitemid 46291834)
8. Kim R, Emi M, Matsuura K, Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 2007; 14: 1-11. (Pubitemid 44952228)
9. O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006; 12: 2902-2911.
10. Vollmer J, Jepsen JS, Uhlmann E, Schetter C, Jurk M, Wader T et al. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 2004; 14: 23-31. (Pubitemid 38524632)
11. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
12. Veedu RN, Wengel J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 2009; 6: 321-323.
13. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
14. Hüttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nückel H et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006; 20: 1774-1782. (Pubitemid 44574989)
15. Seiffert M, Stilgenbauer S, Döhner H, Lichter P. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007; 21: 1977-1983. (Pubitemid 47299973)
16. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997. (Pubitemid 26189840)
17. Jahrsdörfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72: 83-92.
18. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009; 146: 282-291.
19. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, Zheng B et al. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 2007; 109: 1611-1619. (Pubitemid 46239595)
20. Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007; 179: 5947-5957.
21. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008; 180: 800-808.
22. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 2005; 11: 1181-1189. (Pubitemid 40175769)
23. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008; 44: 1829-1834.
24. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104: 1428-1434. (Pubitemid 39166521)
25. Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wyrich R, Thykjaer T et al. Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn 2007; 9: 452-458. (Pubitemid 47434111)
26. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81-88. (Pubitemid 32095121)
27. Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukocyte Biol 2005; 77: 378-387.
28. Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Rommele M, Leja A et al. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 2006; 16: 83-93.
29. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 507-516.
30. Rozkova D, Novotna L, Pytlik R, Hochova I, Kozak T, Bartunkova J et al. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer 2010; 126: 1132-1143.
31. Spaner DE, Shi Y, White D, Shaha S, He L, Masellis A et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2010; 24: 222-226.
32. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8T cells. J Immunol 2003; 170: 4905-4913. (Pubitemid 36554719)
33. Dürig J, Ebeling P, Grabellus F, Sorg UR, Möllmann M, Schütt P et al. A novel nonobese diabetic/severe combined immunodefi-cient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007; 67: 8653-8661.